Friedman, A. M. (2025). Is it time for a large trial to evaluate aspirin for obstetric venous thromboembolism prophylaxis? The Lancet Haematology. https://doi.org/10.1016/s2352-3026(24)00374-0

Wierda, W. G., Shah, N. N., Cheah, C. Y., Lewis, D., Hoffmann, M. S., Coombs, C. C., Lamanna, N., Ma, S., Jagadeesh, D., Munir, T., Wang, Y., Eyre, T. A., Rhodes, J. M., McKinney, M., Lech-Maranda, E., Tam, C. S., Jurczak, W., Izutsu, K., Alencar, A. J., … Ghia, P. (2024). Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. The Lancet Haematology, 11(9), e682–e692. https://doi.org/10.1016/s2352-3026(24)00172-8

Chakraborty, R. (2024). Clinical implications and insights from patient-reported outcome data in KarMMa-3. The Lancet Haematology, 11(3), e175–e176. https://doi.org/10.1016/s2352-3026(24)00028-0

Chakraborty, R., Milani, P., Palladini, G., & Gertz, M. (2023). Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. The Lancet Haematology, 10(11), e936–e940. https://doi.org/10.1016/s2352-3026(23)00175-8

Pecker, L. H., Oteng-Ntim, E., Nero, A., Lanzkron, S., Christianson, M. S., Woolford, T., Meacham, L. R., & Mishkin, A. D. (2023). Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care. The Lancet Haematology, 10(3), e225–e234. https://doi.org/10.1016/s2352-3026(22)00353-2

Ryu, Y. K., & Amengual, J. E. (2022). Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. The Lancet Haematology, 9(7), e463–e465. https://doi.org/10.1016/s2352-3026(22)00169-7

Cogan, J. C., Vianna, P. G., & Akpan, I. J. (2022). Neutrophil-erythrocyte rosettes suggestive of Coombs-negative autoimmune haemolysis. The Lancet Haematology, 9(4), e312. https://doi.org/10.1016/s2352-3026(21)00373-2

Heaney, M. L. (2022). Can the treatment of myeloproliferative neoplasms be both good and bad for you? The Lancet Haematology, 9(1), e3–e4. https://doi.org/10.1016/s2352-3026(21)00371-9

Kahn, J. M., Pei, Q., Friedman, D. L., Kaplan, J., Keller, F. G., Hodgson, D., Wu, Y., Appel, B. E., Bhatia, S., Henderson, T. O., Schwartz, C. L., Kelly, K. M., & Castellino, S. M. (2022). Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. The Lancet Haematology, 9(1), e49–e57. https://doi.org/10.1016/s2352-3026(21)00349-5